CTAS vs OSTX · P/E 51, rev $11.26B vs $74.1M cap
Cintas Corporation (CTAS) versus OS Therapies Incorporated (OSTX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
OS Therapies Incorporated (OSTX) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
OSTX does not have a complete income-statement cache yet.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. OSTX currently screens at market cap $74.1M.
Not investment advice. Open the CTAS and OSTX stock pages for the full models.
Not investment advice.